Regardless of Luminal A and B treatment differences, with larger share and earlier use of chemotherapy in the latter group, long-term OS was the same which could question the common recommendation of avoiding early use of chemotherapy in HR+/HER2- breast cancer. This evidence concerns the gene ERBB2 and breast cancer.